September 29, 2017
Protomer Technologies invited to attend the Southern California Biomedical Council annual conference in Long Beach.
August 18, 2017
Los Angeles mayor Eric Garcetti thanks Protomer Technologies for commitment to creating opportunities for dieverse, local students, and fostering entrepreneurship within the region’s next generation of scientists.
June 29, 2017
Protomer co-founder, Prof. David Tirrell, the Ross McCollum-William H. Corcoran Professor of Chemistry and Chemical Engineering and the director of the Beckman Institute, will become Caltech’s tenth provost.
June 14, 2017
Seth Lieblich of Protomer Technologies and Prof. David Tirrell at Caltech publish their discovery of novel fast acting and ultra-stable insulins in the Journal of American Chemical Society (JACs).
June 1, 2017
Protomer Technologies to attend the 2017 Biotechnology Innovation Organization (BIO) international convention in San Diego, CA.
May 9, 2017
Protomer Technologies to attend the 77th annual American Diabetes Association meeting in San Diego, CA.
January 26, 2017
Protomer Technologies CEO Alborz Mahdavi invited to present as a speaker at the JDRF mission summit in San Francisco, CA.
Alborz Mahdavi will speak with supporters of smart insulin work and T1D groups to discuss the potential and promise of smart insulin therapy.
Jan 20, 2017
Protomer Technologies invited to attend the J.P.Morgan annual healthcare conference and Biotech Showcase in San Francisco, CA: Alborz Mahdavi to speak as an invited panelist at the Biotech Showcase panel discussion on Type 1 diabetes.
Alborz Mahdavi will discuss smart insulin concept at the Biotech Showcase panel discussion on novel therapies, devices and diagnostics on the horizon for type 1 diabetes.
September 27, 2016
May 10, 2016
Protomer Technologies CEO Alborz Mahdavi invited to attend the JDRF inaugural glucose responsive insulin workshop in New York.
To explore the ideal insulin, JDRF and the Leona M. and Harry B. Helmsley Charitable Trust recently hosted leading investigators, industry representatives and patient advocates –all great minds who could create the next big game-changer for T1D. They identified the major challenges to advance the development of GRI and brainstormed about ways to spur the ideal profile for first generation therapies. The meeting was divided into presentations by top investigators who then conducted breakout groups addressing various questions from how to cultivate more and current GRI interventions, to how to create a pathway for timely review of GRI candidates through regulatory agencies.
February 26, 2016
Protomer Technologies CEO Alborz Mahdavi discusses Protomer’s work on smart insulin with Insulinnation.
Insulinnation.com interviews Alborz Mahdavi on Protomer’s work on smart insulin and glucose responsive insulin therapy.
February 25, 2016
Protomer Technologies receives support from JDRF and Sanofi for development of its glucose responsive insulin.
Juvenile Diabetes Research Foundation, the leading global organization funding and advocating for type 1 diabetes (T1D), and Sanofi USA Inc., a subsidiary of Sanofi, one of the largest insulin manufacturers in the world partner to support Protomer Technologies program in glucose responsive insulin.